EyePoint Pharmaceuticals, Inc. — Director's Dealing 2017

Jun 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2017-06-14

Reporting Person: Lurker Nancy (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-14	Common Stock	P	56700	$1.763	Acquired	56700	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.72 to $1.80. The reporting person undertakes to provide pSivida Corp., any security holder of pSivida Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.